Your browser doesn't support javascript.
loading
Development of a recombinant anti-VEGFR2-EPCAM bispecific antibody to improve antiangiogenic efficiency.
Barzaman, Khadijeh; Samadi, Mitra; Moradi-Kalbolandi, Shima; Majidzadeh-A, Keivan; Salehi, Malihe; Jalili, Neda; Jazayeri, Mir Hadi; Khorammi, Samaneh; Darvishi, Behrad; Siavashi, Vahid; Shekarabi, Mahdi; Farahmand, Leila.
Afiliación
  • Barzaman K; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran; Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Samadi M; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Moradi-Kalbolandi S; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Majidzadeh-A K; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Salehi M; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Jalili N; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Jazayeri MH; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Khorammi S; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Darvishi B; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Siavashi V; Department of Clinical Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
  • Shekarabi M; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: M_Shekarabi@yahoo.com.
  • Farahmand L; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. Electronic address: laylafarahmand@gmail.com.
Exp Cell Res ; 405(2): 112685, 2021 08 15.
Article en En | MEDLINE | ID: mdl-34090863
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Inhibidores de la Angiogénesis / Molécula de Adhesión Celular Epitelial / Neovascularización Patológica Límite: Humans Idioma: En Revista: Exp Cell Res Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Inhibidores de la Angiogénesis / Molécula de Adhesión Celular Epitelial / Neovascularización Patológica Límite: Humans Idioma: En Revista: Exp Cell Res Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos